Clinical significance of primary prophylactic pegylated-granulocyte-colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non-small cell lung cancer.
Whether primary prophylactic pegylated-granulocyte-colony stimulating factor (PEG-G-CSF) should be administered immediately after the initiation of ramucirumab plus docetaxel (DR) to prevent the occurrence of febrile neutropenia (FN) is unclear. Our retrospective study aimed to elucidate whether PEG-G-CSF could control the occurrence of FN as a result of DR in patients with previously treated non-small-cell lung cancer. Thirty-three patients with previously treated non-small-cell lung cancer who had received DR were eligible for our analysis. Of the 33 patients, 29 received prophylactic PEG-G-CSF immediately after DR, but none developed FN. However, FN was observed in 2 (50%) of the 4 patients that were not administered PEG-CSF. The overall response and disease control rates in the 29 patients with prophylactic PEG-GSF were 31% and 62%, respectively. The median progression-free and overall survival rates of the patients with and without prophylactic PEG-GSF were 177 and 163 days (P = 0.20), and 628 and 274 days (P = 0.13), respectively. Primary prophylactic PEG-G-CSF suppressed the occurrence of FN secondary to the administration of DR.
['Mouri|Atsuto|A|', 'Kaira|Kyoichi|K|0000-0001-5548-7686', 'Shiono|Ayako|A|', 'Yamaguchi|Ou|O|', 'Murayama|Yoshitake|Y|', 'Kobayashi|Kunihiko|K|', 'Kagamu|Hiroshi|H|']
D000328:Adult D000368:Aged D061067:Antibodies, Monoclonal, Humanized D000971:Antineoplastic Combined Chemotherapy Protocols D002289:Carcinoma, Non-Small-Cell Lung D000077143:Docetaxel D064147:Febrile Neutropenia D005260:Female D016179:Granulocyte Colony-Stimulating Factor D006801:Humans D008175:Lung Neoplasms D008297:Male D008875:Middle Aged D011092:Polyethylene Glycols D065129:Pre-Exposure Prophylaxis D011994:Recombinant Proteins D012189:Retrospective Studies D016019:Survival Analysis D016896:Treatment Outcome
ramucirumab Docetaxel prophylactic G-CSF